Administration of zolpidem was associated with a significantly higher risk of falls in a Mayo Clinic study published online in the Journal of Hospital Medicine. The study included hospital patients of a broad range of ages. After accounting for a range of confounders, the researchers found that one additional fall could be expected for every 55 inpatients who received zolpidem. Patients receiving zolpidem were more than three times as likely to fall as were people who were prescribed it but did not receive it. Dr. Bhanu Prakash Kolla at the Mayo Clinic's Center for Sleep Medicine in Rochester, Minn., and colleagues analyzed falls among 16,320 patients admitted to Mayo Clinic hospitals in 2010. Using an electronic pharmacy database and patient records, the authors compared the rate of falls among patients who were actually administered zolpidem to the rate among those who did not receive the medication despite being prescribed it “as needed.” The 4,962 patients who received zolpidem had a fall rate of 3.04% (151 falls), compared with 0.71% (81 falls) in the 11,358 patients who were not administered zolpidem while in the hospital. Incidentally, patients not prescribed zolpidem (n = 25,627) had a fall rate of 1.42%, which was slightly lower than the overall fall rate of 1.47% among all patients prescribed zolpidem, whether they received it or not. The authors recommended that, given the current absence of evidence for other safer hypnotic alternatives for inpatients, “nonpharmacological measures to improve the sleep of hospitalized patients should be investigated as preferred methods to provide safe relief from complaints of disturbed sleep.” The researchers controlled for confounders that may increase fall risk, including age, length of hospital stay, being on a surgical floor, zolpidem dose, visual impairment, gait abnormalities, cognitive impairment/dementia, insomnia, delirium, comorbidities (measured with the Charlson comorbidity index), and patient's Hendrich's fall risk score. The analysis also controlled for medications that patients received in the 24 hours before the fall that are already associated with an increased fall risk, including antidepressants, antipsychotics, antihistamines, sedative antidepressants including trazodone and mirtazapine, benzodiazepines, and opioids. A univariate analysis revealed that all factors significantly associated with a higher fall rate included zolpidem use (OR = 4.37), being male (OR = 1.36), and having insomnia (OR = 2.37) or delirium (OR = 4.96), as well as increasing age, zolpidem dose, comorbidity scores, and fall risk scores. When the researchers accounted for all statistically significant additional fall risk factors, the association between zolpidem use and fall risk was still significant with an OR of 6.39. There was no statistically significant association identified for the other medications accounted for in the analysis. The study was funded through the Mayo Clinic's fellowship training program, and the authors had no conflict of interest to disclose. Editor's NoteAlthough this study involved hospitalized patients, there's no reason to suspect that things would be any different in the nursing home setting. It's no surprise that a hypnotic, potentially anterograde-amnestic drug would be associated with an increase in falls, but the fourfold increase in risk reported in this study is pretty impressive.Falls are most certainly a bad thing. While quality of life (including good sleep) is an important goal for our residents, we may want to consider whether the benefits of hypnotic therapy (and not just zolpidem, obviously) truly outweigh the risks. And if we are using these meds, it's probably a good idea to disclose these specific risks to our residents and their decision makers.–Karl Steinberg, MD, CMD,Editor in Chief Although this study involved hospitalized patients, there's no reason to suspect that things would be any different in the nursing home setting. It's no surprise that a hypnotic, potentially anterograde-amnestic drug would be associated with an increase in falls, but the fourfold increase in risk reported in this study is pretty impressive. Falls are most certainly a bad thing. While quality of life (including good sleep) is an important goal for our residents, we may want to consider whether the benefits of hypnotic therapy (and not just zolpidem, obviously) truly outweigh the risks. And if we are using these meds, it's probably a good idea to disclose these specific risks to our residents and their decision makers. –Karl Steinberg, MD, CMD, Editor in Chief